MYC rearrangements, either alone or in combination with BCL2 rearrangements (“double-hit” lymphomas), have been associated with resistance or a poor response to therapy and inferior survival in systemic DLBCL [7]–[9], [39]. This evidence concerns the gene BCL2 and lymphoma.